Company Description
Lexaria Bioscience Corp. operates as a biotechnology company.
It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.
The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids.
Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods.
Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
| Country | Canada |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Christopher A. Bunka |
Contact Details
Address: 100 - 740 Mccurdy Road Kelowna, A1 V1X 2P7 British Columbia, Canada | |
| Phone | 250-765-6424 |
| Website | lexariabioscience.com |
Stock Details
| Ticker Symbol | LEXX |
| Exchange | NASDAQ |
| Fiscal Year | September - August |
| Reporting Currency | USD |
| CIK Code | 0001348362 |
| CUSIP Number | 52886N406 |
| ISIN Number | US52886N4060 |
| Employer ID | 20-2000871 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher A. Bunka | Chairman and Chief Executive Officer |
| John M. Docherty M.Sc. | President and Director |
| Nelson D. Cabatuan CPA | Chief Financial Officer |
| Kristin Hamilton | Director of Operations |
| Vanessa Carle | Head of Legal |
| Dr. Philip N. Ainslie Ph.D. | Advisor and Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2024 | 10-Q | Quarterly Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 20, 2024 | EFFECT | Notice of Effectiveness |
| Mar 20, 2024 | 424B3 | Prospectus |
| Mar 18, 2024 | UPLOAD | Filing |
| Mar 15, 2024 | 8-K | Current Report |
| Mar 12, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 6, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 1, 2024 | 8-K | Current Report |
| Feb 16, 2024 | 8-K | Current Report |